Song Z, Zhou Q, Zhang JL, Ouyang J, Zhang ZY. Correction to: Marker Ki-67 is a potential biomarker for the diagnosis and prognosis of prostate cancer based on two cohorts. World J Clin Cases 2024; 12(36): 6950-6951 [DOI: 10.12998/wjcc.v12.i36.6950]
Corresponding Author of This Article
Zhi-Yu Zhang, MD, PhD, Doctor, Surgeon, Department of Urology, The First Affiliated Hospital of Soochow University, No. 188 Shizi Street, Gusu District, Suzhou 215000, Jiangsu Province, China. abner_666@126.com
Research Domain of This Article
Medicine, Research & Experimental
Article-Type of This Article
Correction
Open-Access Policy of This Article
This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
Zhen Song, Department of Urology, Taixing People’s Hospital, Taizhou 225400, Jiangsu Province, China
Zhen Song, Jiang-Lei Zhang, Jun Ouyang, Zhi-Yu Zhang, Department of Urology, The First Affiliated Hospital of Soochow University, Suzhou 215000, Jiangsu Province, China
Qi Zhou, Department of Reproductive Medicine Center, The First Affiliated Hospital of Soochow University, Suzhou 215000, Jiangsu Province, China
Author contributions: All authors have written, read and approved the final draft.
Conflict-of-interest statement: All the authors report no relevant conflicts of interest for this article.
Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: Zhi-Yu Zhang, MD, PhD, Doctor, Surgeon, Department of Urology, The First Affiliated Hospital of Soochow University, No. 188 Shizi Street, Gusu District, Suzhou 215000, Jiangsu Province, China. abner_666@126.com
Received: August 8, 2024 Revised: September 30, 2024 Accepted: October 21, 2024 Published online: December 26, 2024 Processing time: 83 Days and 20.7 Hours
Abstract
This is an erratum to the published paper titled “Marker Ki-67 is a potential biomarker for the diagnosis and prognosis of prostate cancer based on two cohorts”. We have discovered that Reference 4 was cited incorrectly. We sincerely apologize for this inadvertent error. Please note that these corrections do not impact our results.
Core Tip: This manuscript is to correct the Reference 4 of "Marker Ki-67 is a potential biomarker for the diagnosis and prognosis of prostate cancer based on two cohorts. World J Clin Cases 2024;12(1): 32-41 PMID: 38292624 DOI: 10.12998/wjcc.v12.i1.32".
Citation: Song Z, Zhou Q, Zhang JL, Ouyang J, Zhang ZY. Correction to: Marker Ki-67 is a potential biomarker for the diagnosis and prognosis of prostate cancer based on two cohorts. World J Clin Cases 2024; 12(36): 6950-6951
In the article[1], the sentence "In China, PCa has surpassed bladder and kidney cancers in terms of incidence and mortality, and is currently the most common tumor in adult urology[4]" incorrectly cites Reference 4 as “Reference 4: Marsh HP, Bowler IC, Watson CJ. Successful treatment of Rhodococcus equi pulmonary infection in a renal transplant recipient. Ann R Coll Surg Engl 2000; 82: 107-108.” The correct Reference 4 should be: “Reference 4: Liu J, Dong L, Zhu Y, Dong B, Sha J, Zhu HH, Pan J, Xue W. Prostate cancer treatment - China’s perspective. Cancer Lett 2022; 550: 215927 [PMID: 36162714 DOI: 10.1016/j.canlet.2022.215927]”. Please note that these corrections do not impact our results.
Footnotes
P-Reviewer: N/A S-Editor: Li L L-Editor: A P-Editor: Yu HG
Song Z, Zhou Q, Zhang JL, Ouyang J, Zhang ZY. Marker Ki-67 is a potential biomarker for the diagnosis and prognosis of prostate cancer based on two cohorts.World J Clin Cases. 2024;12:32-41.
[PubMed] [DOI][Cited in This Article: ][Reference Citation Analysis (7)]
